Loading…
Loading…
PTC does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for PTC and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for PTC and 80,000+ other tickers.
See exactly how PTC's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PTC and 80,000+ other tickers.
PTC Inc. operates as a global provider of software and services, with its market presence extending across the Americas, Europe, and the Asia Pacific regions. The company's business is organized into two primary divisions: Software Products and Professional Services. Among its key offerings is the ThingWorx platform, which furnishes enterprises with a suite of functionalities to drive digital innovation across their operations. These solutions are characterized by ease of creation and deployment, scalability for future demands, and their ability to accelerate value realization for customers…
In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142) “Speedy,” a PTC-2105-treated mouse now more than 167 weeks old, has outlived every saline-treated negative control in his study by more than 20% and remains active day and night New “Team Speedy” webpage, launching today at eossenolytix.com/team-speedy, invites the public to watch Speedy, predict how far he will go, and sign up for milestone alerts BERLIN and HOUSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. (“Eos” or the “Company”) a biotechnology company developing mitochondria-targeted geropeptides to improve healthspan, today presented new preclinical survival, healthspan and mechanism-of-action data for its lead candidate, PTC-2105, in an Industry Keynote Address at the 17th World Congress on Targeting Mitochondria 2026 in Berlin. The keynote, “Building on the Foundation of Four: Advancing Mitochondrial-Targeted Geropeptide Medicine,” delivered by Dr. Kevin Slawin, Founder and CEO of Eos SENOLYTIX, acknowledged the contribution of Dr. Hazel Szeto, who with Dr. Peter Schiller co-discovered the four amino acid peptide, SS-31, (“elamipretide”), the first FDA-approved therapeutic that directly targets mitochondria.
Brings internal teams, suppliers, and partners into secure Rooms to review 2D and 3D product content in the browser Keeps comments, markups, versions, and decisions in context to accelerate reviews and reduce rework Leverages AI to turn complex discussions into clear and actionable next steps and Windchill connectivity to carry decisions into downstream execution BOSTON, Oct. 21, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the launch of its PTC Jetstream™ cloud and AI-native product collaboration solution to connect people, product information, and decisions – enabling product companies to move faster, catch issues earlier, and bring great products to market. As products become more complex, organizations need to bring expertise from across the business into the development process without slowing innovation, but reviews and discussions that shape a product are often scattered across disconnected tools and processes.
BOSTON, Oct. 19, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) will release its fiscal 2026 fourth quarter and full year results on Wednesday, November 4th after the stock market closes. As previously announced on October 5th, 2026, PTC entered into a definitive agreement to be acquired by Schneider Electric.
WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial results and provide a business update on Thursday, Oct. 29, 2026, at 4:30 p.m.
Optimizes service parts across complex global supply network Transforms planning productivity through exception-based management AI-powered intelligence built on deep service supply chain expertise and proven optimization science BOSTON, Oct. 15, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that the United States Air Force (USAF) has extended its use of PTC's Servigistics® service supply chain optimization solution as part of its Enterprise Supply Chain Analysis, Planning, and Execution (ESCAPE) program. The renewal extends a nearly decade-long relationship focused on modernizing the Air Force service supply chain and improving aircraft and system readiness.